New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Researchers unveil the origin of second pediatric cancers and chemotherapy-induced mutations in healthy tissues

Researchers unveil the origin of second pediatric cancers and chemotherapy-induced mutations in healthy tissues

byInstitute for Research in Biomedicine (IRB Barcelona)The origin of second solid tumors of cases 3 (A–D) and 4 (E–F). A, Eight years after the development of NB, the child presented with MRT. B
Oncology March 30,2024
Researchers unveil the origin of second pediatric cancers and chemotherapy-induced mutations in healthy tissues

Researchers unveil the origin of second pediatric cancers and chemotherapy-induced mutations in healthy tissues

byInstitute for Research in Biomedicine (IRB Barcelona)The origin of second solid tumors of cases 3 (A–D) and 4 (E–F). A, Eight years after the development of NB, the child presented with MRT. B
Oncology March 30,2024
Chemo toxicity: A common gene test could save hundreds of lives each year

Chemo toxicity: A common gene test could save hundreds of lives each year

by Arthur Allen, KFF Health NewsCredit: Unsplash/CC0 Public DomainOne January morning in 2021, Carol Rosen took a standard treatment for metastatic breast cancer. Three gruesome weeks later, she died
Oncology March 30,2024
Chemo toxicity: A common gene test could save hundreds of lives each year

Chemo toxicity: A common gene test could save hundreds of lives each year

by Arthur Allen, KFF Health NewsCredit: Unsplash/CC0 Public DomainOne January morning in 2021, Carol Rosen took a standard treatment for metastatic breast cancer. Three gruesome weeks later, she died
Oncology March 30,2024
Drug-pricing program improves prostate cancer treatment adherence, finds study

Drug-pricing program improves prostate cancer treatment adherence, finds study

by Nicole Fawcett,University of MichiganCredit: Unsplash/CC0 Public DomainProstate cancer patients receiving care at hospitals that are part of a special drug-pricing program were more likely to
Oncology March 30,2024
Drug-pricing program improves prostate cancer treatment adherence, finds study

Drug-pricing program improves prostate cancer treatment adherence, finds study

by Nicole Fawcett,University of MichiganCredit: Unsplash/CC0 Public DomainProstate cancer patients receiving care at hospitals that are part of a special drug-pricing program were more likely to
Oncology March 30,2024
Revealing characteristics of circulating cell-free RNA in the blood of liver cancer patients

Revealing characteristics of circulating cell-free RNA in the blood of liver cancer patients

byScience China PressMOF materials efficiently enrich circulating nucleic acids (cfDNA and cfRNA) in blood through a simple operational process, enabling various downstream nucleic acid detectio
Oncology March 30,2024
Revealing characteristics of circulating cell-free RNA in the blood of liver cancer patients

Revealing characteristics of circulating cell-free RNA in the blood of liver cancer patients

byScience China PressMOF materials efficiently enrich circulating nucleic acids (cfDNA and cfRNA) in blood through a simple operational process, enabling various downstream nucleic acid detectio
Oncology March 30,2024
'3D mammography' almost halves the incidence of breast cancer between two screening tests in clinical trial

'3D mammography' almost halves the incidence of breast cancer between two screening tests in clinical trial

byUniversity of CórdobaDBT interval carcinoma. A 60-year-old asymptomatic patient who underwent a repeat mammographic study 20months after the screening study interpreted as normal due to
Oncology March 30,2024
'3D mammography' almost halves the incidence of breast cancer between two screening tests in clinical trial

'3D mammography' almost halves the incidence of breast cancer between two screening tests in clinical trial

byUniversity of CórdobaDBT interval carcinoma. A 60-year-old asymptomatic patient who underwent a repeat mammographic study 20months after the screening study interpreted as normal due to
Oncology March 30,2024
Study discusses liquid biopsy as a game changer for early lung cancer detection

Study discusses liquid biopsy as a game changer for early lung cancer detection

by Cactus CommunicationsCredit: CC0 Public DomainIn 2020, 1.8 million people succumbed to lung cancer. The late-stage discovery of lung cancer is one of the glaring challenges faced by the medical com
Oncology March 30,2024
Study discusses liquid biopsy as a game changer for early lung cancer detection

Study discusses liquid biopsy as a game changer for early lung cancer detection

by Cactus CommunicationsCredit: CC0 Public DomainIn 2020, 1.8 million people succumbed to lung cancer. The late-stage discovery of lung cancer is one of the glaring challenges faced by the medical com
Oncology March 30,2024
New research results explore the safety of short-term cultivated CAR T cells in cancer immunotherapy

New research results explore the safety of short-term cultivated CAR T cells in cancer immunotherapy

by Susanne Stöcker, Paul-Ehrlich-Institut - Bundesinstitut für Impfstoffe und biomedizinische ArzneimittelTo make CAR T cells available to all patients, various strategies facilitating the manufacturi
Oncology March 30,2024
New research results explore the safety of short-term cultivated CAR T cells in cancer immunotherapy

New research results explore the safety of short-term cultivated CAR T cells in cancer immunotherapy

by Susanne Stöcker, Paul-Ehrlich-Institut - Bundesinstitut für Impfstoffe und biomedizinische ArzneimittelTo make CAR T cells available to all patients, various strategies facilitating the manufacturi
Oncology March 30,2024
Delayed treatment effect predicting (DTEP) model found to enhance precision in immuno-oncology trial designs

Delayed treatment effect predicting (DTEP) model found to enhance precision in immuno-oncology trial designs

by Science China PressAt the trial design stage, by inputting information on treatment stage, cancer type, and experimental and control arm regimens, investigators can utilize the nomogram or web
Oncology March 30,2024
Delayed treatment effect predicting (DTEP) model found to enhance precision in immuno-oncology trial designs

Delayed treatment effect predicting (DTEP) model found to enhance precision in immuno-oncology trial designs

by Science China PressAt the trial design stage, by inputting information on treatment stage, cancer type, and experimental and control arm regimens, investigators can utilize the nomogram or web
Oncology March 30,2024
Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

by NRG OncologyResults from the Phase III NRG Oncology NRG-GU003 clinical trial comparing hypofractioned post-prostatectomy radiotherapy (HYPORT) to conventionally fractioned post-prostatectomy radiot
Oncology March 30,2024
Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

by NRG OncologyResults from the Phase III NRG Oncology NRG-GU003 clinical trial comparing hypofractioned post-prostatectomy radiotherapy (HYPORT) to conventionally fractioned post-prostatectomy radiot
Oncology March 30,2024
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

by St. Jude Children's Research HospitalCredit: Unsplash/CC0 Public DomainFibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The d
Oncology March 30,2024
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

by St. Jude Children's Research HospitalCredit: Unsplash/CC0 Public DomainFibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The d
Oncology March 30,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com